Taiga Biotechnologies

Description

• Taigas technologies provide a unique opportunity to develop and commercialize cell therapies and protein and small molecule lead compounds in a diverse set of therapeutic areas, including cancer, hematology, immunology, neurology, cardiovascular disease, and solid organ transplantation.The company is currently focused on two core oncology programs, both enabled by the companys unique and proprietary stem cell technologies:1. Stem-cell therapeutics for the treatment of hematological malignancies via hematopoietic stem cell transplant. The lead indications for this program include acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). Taigas main priority is the development of a stem cell therapy to test in a clinical setting.2.Hematology-focused drug discovery. Taiga also seeks to establish collaborative partnerships with pharmaceutical and biotech companies in the cancer space to discover, test and develop protein and small molecule therapeutics. Early collaborations will focus on unmet needs in leukemia and Non-Hodgkins Lymphoma. Taiga is in discussions with several of the industrys top cancer companies to establish potential drug discovery collaborations for the future of Taiga Biotechnologies. The specific oncology indications targeted by Taigas early programs represent billion dollar markets.
• 

  Headquarters:12635 East Montview Boulevard , Aurora, Colorado, United States

  More
• 

  Phone Number: +1 720-859-3547

• 

  Website: https://www.taigabiotech.com

• 

  Employees:13

• 

  Revenue:$10 - 50M

• 

  Legal Name:Taiga Biotechnologies

• Taiga Biotechnologies's Social Media

  
• Is this data correct?

• |  NAICS Code: 541713  |

  Show More